Viracta Therapeutics jumps on 'orphan' status for cancer treatment

Viracta Therapeutics

29/11/2021 13:29

** Shares of cancer treatment developer  VIRX.O  jump 11.6%
to $5.40 premarket 
    ** VIRX set for best session in almost six months
    ** Co says FDA granted "orphan drug" status to its oral
combination product candidate for the treatment of Epstein Barr
virus-positive diffuse large B-cell lymphoma  urn:newsml:reuters.com:*:nASA02U1V
    ** The designation is given to drugs that treat rare
diseases; it gives a seven-year period of exclusivity from
product approval    
    ** VIRX down ~31% YTD as of last close
    

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))